Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy.

F C Moazedi-FuerstA LacknerS M KreuzerK EllerB OdlerG KovacsH FlickE TalakicJ HermannN VenhoffA VenhoffF HafnerM BrodmannPhilipp JudB Yazdani-BiukiR HusicW SalmhoferM H StradnerW B GraningerJ ThielH P Brezinschek

Published in: Journal of autoimmunity (2024)

SSc was effectively and safely treated with low-dose RTX quarterly. RCTs are warranted to validate the advantage of continuous B cell depletion by quarterly low-dose RTX administration compared to other treatment intervals.

Keyphrases

low dose
systemic sclerosis
high dose
interstitial lung disease
stem cells
rheumatoid arthritis
combination therapy